Antibody Avidity Meets Multiple Myeloma
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Swan D, Lynch K, Gurney M, ODwyer M
. Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. Ther Adv Hematol. 2019; 10:2040620719854171.
PMC: 6582283.
DOI: 10.1177/2040620719854171.
View
2.
Lu Q, Yang D, Li H, Niu T, Tong A
. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024; 5(1):25.
PMC: 11222366.
DOI: 10.1186/s43556-024-00188-w.
View
3.
Parrondo R, Ailawadhi S, Cerchione C
. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives. Front Oncol. 2024; 14:1394048.
PMC: 11039948.
DOI: 10.3389/fonc.2024.1394048.
View
4.
Carretero-Iglesia L, Hall O, Berret J, Pais D, Estoppey C, Chimen M
. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nat Cancer. 2024; 5(10):1494-1514.
PMC: 11505469.
DOI: 10.1038/s43018-024-00821-1.
View
5.
van de Donk N, Richardson P, Malavasi F
. CD38 antibodies in multiple myeloma: back to the future. Blood. 2017; 131(1):13-29.
DOI: 10.1182/blood-2017-06-740944.
View